RNAZ Projected Dividend Yield
Com Par $0.0001/TransCode Therapeutics Inc ( NASDAQ : RNAZ )TransCode Therapeutics, Inc. is a clinical-stage oncology company focused on treating metastatic disease. Co. is focused on treating cancer through the design and delivery of ribonucleic acid (RNA) therapeutics based on its TTX nanoparticle platform. Co.'s lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. 20 YEAR PERFORMANCE RESULTS |
RNAZ Dividend History Detail RNAZ Dividend News RNAZ Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |